Loading
A phase 3 trial of Osilodrostat in Pituitary tumours, run by Novartis Pharmaceuticals, completed.
Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease is a phase 3 interventional study registered as NCT02697734 by Novartis Pharmaceuticals, with 73 participants recorded, started 2016-10-03 and reaching its primary completion in 2019-06-19. Interventions recorded: osilodrostat, osilodrostat Placebo. Conditions recorded: Cushing's Disease.
Linked to the drug Osilodrostat because the registry names it among its interventions and Pituitary tumours among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
73 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2021-10-19), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Percentage of Randomized Participants With a Complete Responseprimary | Osilodrostat Group | 48 | 37 participants | - | <.0001 | link |
| Osilodrostat Placebo Group | 25 | 2 participants |
Shares Osilodrostat, Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma, Novartis and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma, Novartis and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma, Novartis and the tag pipeline.
Shares Osilodrostat, Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma, Novartis and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.